CTLA4 and cancer: ,20 Furthermore, the combination of anti-PD-L1 + anti- cytotoxic T lymphocyte associated protein 4 (CTLA-4) leads to both increased survival times and induces long-term tumor regression in 50% of the population, featuring acquired resistance to cancer re-challenge.19